New drug plus immunotherapy for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new oral drug (HC-7366) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced clear cell kidney cancer. The goal is to see if adding this new drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have clear cell renal cell carcinoma (a common type of kidney cancer) that has spread to other parts of the body (stage IV).
- Depending on the trial group: either you have not had any prior treatment for advanced kidney cancer, or you have had one or two prior treatments that included an immunotherapy.
- You must be able to do daily activities with little to no help (ECOG 0 or 1).
- You must have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether removing the kidney tumor (cytoreductive nephrectomy) before treatment can improve outcomes for people with metastatic clear-cell kidney cancer. All participants are expected to receive standard immunotherapy (nivolumab plus ipilimumab), and the study focuses on the role of surgery in the “immuno-oncology era.”
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial compares two immunotherapy combinations—nivolumab/relatlimab/ipilimumab vs. nivolumab/ipilimumab—as first treatment for advanced kidney cancer with clear cell features. It aims to see which combo works better for people who haven't had prior therapy.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Hear when a new Phase 1b trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.